Prime-2-CoV_Beta

BIOLOGICAL2 trials

Sponsors

Speransa Therapeutics, University Hospital Tuebingen

Conditions

COVID-19SARS-CoV-2 Infection

Phase 1

A Study Assessing the Safety, Tolerability, Immunogenicity of COVID-19 Vaccine Candidate PRIME-2-CoV_Beta, Orf Virus Expressing SARS-CoV_2 Spike and Nucleocapsid Proteins

TerminatedNCT05367843

Speransa TherapeuticsSARS-CoV-2 Infection

Start: 2022-06-20End: 2023-11-08Updated: 2024-02-09

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

Active, not recruitingNCT05389319

University Hospital TuebingenCOVID-19

Start: 2022-06-24End: 2026-12-31Target: 96Updated: 2026-06-15

Related Papers

First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster

Vaccines2024-11-185 citations

A novel orf virus vector-based COVID-19 booster vaccine shows cross-neutralizing activity in the absence of anti-vector neutralizing immunity

Human Vaccines & Immunotherapeutics2024-10-147 citations